

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/067224 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 35/00 (2006.01)
A61K 31/65 (2006.01) C07K 16/28 (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:

PCT/US2021/052286

(22) International Filing Date:

28 September 2021 (28.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/084,542 28 September 2020 (28.09.2020) US

(71) Applicant: NAVROGEN, INC. [US/US]; 66 Mount Aire Farm Road, Glen Mills, Pennsylvania 19342 (US).

(72) Inventors: GRASSO, Luigi; 403 Barbara Lane, Bryn Mawr, Pennsylvania 19010 (US). NICOLAIDES,

Nicholas C.; 66 Mount Aire Farm Road, Glen Mills, Pennsylvania 19342 (US). KLINE, James Bradford; 29 Lenape Drive, Morgantown, Pennsylvania 19543 (US).

(74) Agent: KAGAN, Sarah A.; Banner & Witcoff, LTD., 1100 13th Street NW, Suite 1200, Washington, District of Columbia 20005-4051 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: COMPOSITION AND USE OF ALTERNATIVELY FORMATTED ANTI-MESOTHELIN ANTIBODIES FOR THE TREATMENT OF CANCER




Fig. 1A

(57) Abstract: Tumors utilize multiple mechanisms to avoid the host's anti-tumor immune response. Humoral immunosuppression is one of the mechanisms. Tumors produce circulating factors that can suppress antibody or complement-mediated immune responses to enhance their own survival. Mesothelin is a cell surface protein overexpressed by several cancer types that are associated with tumors exhibiting immunosuppressed microenvironments. Anti-mesothelin antibodies are often subject to such immunosuppressive microenvironments. Alternatively formatted anti-mesothelin antibodies, however, are effective in killing mesothelin-expressing cancers irrespective of tumor microenvironment immune status.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*